THE APEX TIMES
A new report says Coinbase wants to launch prediction markets on its platform in the first half of 2027, potentially challenging Robinhood’s role in the genre while Coinbase moves beyond its Kalshi partnership.
Coinbase is reportedly planning to launch its own prediction markets by mid-2027, stepping into a product category that has become closely watched for how quickly it can convert mainstream investors into traders of political, economic, and other future outcomes.
The reported timeline is first half of 2027. The initiative would mark a shift for Coinbase, according to the report, which frames the effort as moving beyond Coinbase’s existing partnership with Kalshi, a well-known prediction market operator. Prediction markets are platforms where participants buy and sell contracts tied to the outcomes of specific events, with payouts based on what actually happens.
The report also positions Coinbase’s move as creating a new competitive pressure point for Robinhood, which has been promoting prediction-style trading through its own market offerings. The implication is that Coinbase would not only broaden its trading feature set, but also increase direct product overlap with a consumer-focused brokerage that has already built marketing around these markets.
In practice, launching prediction markets would require Coinbase to develop or integrate the mechanics for listing contracts, settling outcomes, and managing the trading experience around event-based products. While the report points to the intended launch window and the strategic reason for the shift, it does not provide details in this package about what contract types Coinbase would offer, how its platform would handle settlement and disputes, or whether it would rely on third-party infrastructure beyond Kalshi.
Coinbase, as a major U.S.-based cryptocurrency exchange and broker, has increasingly emphasized a broader “trading and investing” stack rather than only spot crypto. A move into prediction markets, if it proceeds as described, would expand Coinbase’s platform beyond crypto-specific assets into an adjacent trading format that some retail users treat as a casual alternative to traditional investing.
Still, it is not clear from the report how Coinbase would structure the regulatory and operational aspects of event-based contracts, nor what regulatory posture it would take as it scales the offering. Prediction markets can raise distinct legal and compliance questions compared with standard brokerage products, and Coinbase did not outline those specifics in the material reviewed for this story.
The report also does not clarify how Coinbase’s existing Kalshi relationship would change operationally during the transition. For example, it is not stated whether Coinbase would fully replace Kalshi-linked offerings with its own marketplace, run both in parallel, or shift the partnership role to specific product lines or time horizons.
For markets to take the news seriously, investors will likely want follow-up confirmation from Coinbase, such as a product announcement, an updated partnership agreement description, or disclosures that address contract scope and timelines. Until then, the key open question is whether the mid-2027 launch plan is firm or subject to change, given how dependent prediction-market operations can be on regulatory outcomes and settlement processes.
A market-focused note argues the company’s cash-return profile could matter as Wall Street debates whether 2027 can resemble 2022. The company, however, did not provide new disclosure in the cited post.
A market report said the U.S. Securities and Exchange Commission has opened an investigation involving Nvidia as the chipmaker absorbs fallout from a sharp selloff. Investors now have to parse what the agency is looking at and how much the matter could weigh on disclosures and governance.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
Marques Brownlee said he has placed an order for Tesla’s Cybercab following a 2024 challenge, and Tesla CEO Elon Musk replied “fair enough,” saying he would accept delivery.
A new market read on Booz Allen Hamilton Holding points to a sizable gap between the company’s valuation and the cash flow the business can generate, sharpening questions for investors about how durable profits and cash generation are in the defense IT services market.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
A newly announced partnership between Microsoft and Danaher aims to pair AI-assisted capabilities with cloud-based scientific instruments and lab software, including early tools that are already moving toward commercial use.
A new market round-up from Yahoo Finance highlights how lingering discussion among Fed officials about whether interest rates need to rise again can reshape expectations for large, consumer-facing companies like PepsiCo.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A fresh round of holiday changes at Target centers on shopping hours and promotions, a shift the company is indicating as part of how it intends to drive demand into the end of the year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...